ADVFN US – Market Content Editor
-

Boeing Shares Fall After Report of 737 MAX Software Issue
Boeing (NYSE:BA) shares fell 1.9% after The Wall Street Journal reported that the planemaker had identified a software issue affecting an automated navigation function on the 737 MAX. According to the report, the software issue can disable the automated navigation function during a landing following a missed approach. The issue emerged following an update to…
-

Circle Internet Group Shares Fall After CFO Announces Departure
Circle Internet Group (NYSE:CRCL) shares fell 3.5% after the company announced that Chief Financial Officer Jeremy Fox-Geen plans to step down following more than five years in the role. Fox-Geen will remain with Circle through the end of December 2026 to assist with the transition. The company has engaged an executive search firm to help…
-

TruGolf Announces Reverse Stock Split and Leadership Changes
TruGolf Holdings, Inc. (NASDAQ:TRUG) announced a series of corporate developments during September, including a reverse stock split and management changes, as the company continues work on its proposed acquisition of Polymath Research Inc. Founder Chris Jones resigned as chief executive officer, while Chairman Brenner Adams was appointed interim CEO. TruGolf also appointed Jay Heller to…
-

Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients
Adicet Bio, Inc. (NASDAQ:ACET) reported Phase 1 clinical data for prulacabtagene leucel, or prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus with or without lupus nephritis. The data cutoff was August 28, 2026, and included 22 efficacy-evaluable patients, comprising 16 with lupus nephritis and six with extra-renal systemic…
-

ACI Worldwide and Cognizant Complete BASE24-eps Performance Testing on AWS
ACI Worldwide (NASDAQ:ACIW) and Cognizant (NASDAQ:CTSH) announced results from joint performance testing of BASE24-eps, ACI’s card acquiring and issuing software component, deployed on Amazon Web Services. According to ACI Worldwide, the system sustained more than twice the target transaction load for 30 minutes without recording a failed transaction. Across the full test, BASE24-eps processed more…
-

Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract
Scynexis (NASDAQ:SCYX) shares rose 13.9% in pre-market trading after the company announced a contract with the U.S. Biomedical Advanced Research and Development Authority to support development of its SCY-247 antifungal candidate. The BARDA contract provides potential funding of up to approximately $214 million if all options are exercised and could extend for as long as…
-

AngloGold Ashanti Shares Fall 7.3% as Oil Prices and Treasury Yields Rise
AngloGold Ashanti (NYSE:AU) shares fell 7.3% to $91.81 in pre-market trading as crude oil prices and U.S. Treasury yields moved higher and broader U.S. equity markets declined. Brent crude rose above $108 per barrel, while West Texas Intermediate also advanced after U.S. President Donald Trump rejected ceasefire terms presented by Iran. Higher energy prices can…
-

Snowflake Shares Fall After $3.5 Billion Convertible Note Offering
Snowflake (NYSE:SNOW) shares fell 4% on Monday after the enterprise software company announced plans to raise $3.5 billion through a private offering of convertible senior notes. The offering consists of $1.3 billion of convertible notes due in October 2029 and $2.2 billion of notes due in October 2031. The securities will be offered to qualified…
-

Roche Plans Autonomous AI-Driven Laboratories for Drug Development
Roche (USOTC:RHHBY) plans to develop autonomous artificial intelligence-driven laboratories as part of its research and development activities, the Swiss pharmaceutical company said Monday. Aviv Regev, executive vice president of Genentech Research and Early Development, said Roche is pursuing “AI independence” in research and development and has started constructing autonomous AI-driven laboratories. The initiative forms part…
-

Kodiak Sciences Shares Rise After DAYBREAK Phase 3 Trial Results
Kodiak Sciences (NASDAQ:KOD) shares rose 31.9% in pre-market trading after the company released topline results from its DAYBREAK pivotal Phase 3 study evaluating two investigational therapies in patients with wet age-related macular degeneration. The study evaluated Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer), with aflibercept serving as the active comparator. Kodiak hosted a webcast…